The U.S. National Institutes of Health has committed $25 million to better understanding infectious diseases, awarding the cash to the J. Craig Venter Institute, which will apply its sequencing and bioinformatics skills to tackling the field.
With days to go until the European Medicines Agency meets to finalize its clinical trial data policy, the region's ombudsman has confirmed she is probing a possible link between a settlement with AbbVie and a shift in the transparency plans.
Every year the FDA receives hundreds of Freedom of Information Act requests from biopharma companies for adverse-event data, while others take equally laborious steps to access the information. Now the FDA is opening up its adverse-event data through an application programming interface.
A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.
After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Having backed biotech IT businesses like Comprehend Systems and SV Bio in the U.S., high-profile venture firm Sequoia Capital has turned its attention to India. And with a $530 million fund to fuel its ambitions, the California-based VC shop could kick-start the tech and healthcare startup ecosystem in India and across Southeast Asia.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.
Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.
Data gathered by cybersecurity ratings company Bitsight suggests the healthcare and pharmaceutical sectors have fared even worse than retail.
The use of computer-driven approaches from the very first steps in drug discovery through to marketing and the supply chain is reflected in the list of research areas in which the FDA wants to invest in 2014, which is littered with references to in silico modeling, omics and mobile applications.
The potential cost savings generated by risk-based monitoring of clinical trials has led some to tip it as a way to significantly streamline pharma's flabby studies. And that potential has lured tech providers, with Medidata and Parexel both advancing their claims on the market this week.
Broad Institute Director Eric Lander has emphasized the importance of open labs and shared spaces. Yet as Broad expanded, hundreds of scientists ended up spread across four sites. Now Broad has reignited its original vision with the opening of new digs.
Authorities removed more than 19,000 ads on Facebook, Twitter and YouTube that promoted the illegal sale of medicines.
While service providers talk up the convenience and flexibility of moving to the cloud, pharma execs are as likely to flag up the litany of privacy, security and technical risks created by the transition.
Wipro has won a $400 million contract to manage Takeda's infrastructure. Takeda inked the deal to consolidate its operations, with Wipro becoming its primary provider of IT infrastructure management services.
When European politicians voted overwhelmingly in favor of a clinical research data sharing law last month, it looked like a big step forward for transparency campaigners. Yet just weeks later researchers have raised concerns that the European Medicines Agency is already trying to lessen the impact of the legislation.
The rise of omics data in R&D has increased the overlap between biotech and Silicon Valley-style tech startups, with Flatiron Health's recent $130 million round making it a standout example. This week, SolveBio took its first steps on the path established by Flatiron by raising cash from the co-founder of Paypal other other leading tech investors.
Having outlined the ambitious plans for his latest venture in March, J. Craig Venter has begun to flesh out the team and capabilities Human Longevity will need to fulfill his vision.
Bayer and Boehringer Ingelheim outlined plans to increase access to their clinical trial data.
With the U.S. National Institutes of Health's current IT procurement contract ending in November, the agency has laid out its successor: a 10-year contract for laptops, servers and other equipment and services worth up to $20 billion.